REGEN BIOPHARMA, INC. (RGBP) earnings per share
Annual history
Fiscal years 2022 – 2025
USD / SHARE 4 PERIODS
| Period | End | Diluted | Filed |
|---|---|---|---|
| FY 2025 | 2025-09-30 | -$0.05 | 2025-12-30 |
| FY 2024 | 2024-09-30 | -$0.16 | 2025-05-13 |
| FY 2023 | 2023-09-30 | $0.29 | 2023-11-20 |
| FY 2022 | 2022-09-30 | $0.36 | 2022-11-15 |
Quarterly history
Fiscal years 2023 – 2026
USD / SHARE 13 PERIODS
| Period | End | Diluted | Filed |
|---|---|---|---|
| Q2 2026 | 2026-03-31 | $0.00 | 2026-05-14 |
| Q1 2026 | 2025-12-31 | -$0.01 | 2026-02-13 |
| Q4 2025 | 2025-09-30 | -$0.02 | 2025-12-30 |
| Q3 2025 | 2025-06-30 | -$0.01 | 2025-08-11 |
| Q2 2025 | 2025-03-31 | $0.00 | 2025-05-28 |
| Q1 2025 | 2024-12-31 | -$0.13 | 2025-05-16 |
| Q4 2024 | 2024-09-30 | -$0.06 | 2025-05-13 |
| Q3 2024 | 2024-06-30 | -$0.03 | 2024-08-13 |
| Q2 2024 | 2024-03-31 | -$0.03 | 2024-04-24 |
| Q1 2024 | 2023-12-31 | -$0.04 | 2024-01-19 |
| Q4 2023 | 2023-09-30 | $0.10 | 2023-11-20 |
| Q3 2023 | 2023-06-30 | -$0.01 | 2023-07-25 |
| Q1 2023 | 2022-12-31 | $0.23 | 2023-01-19 |
Methodology
Annual rows come from the filer's 10-K and Q1–Q3 rows from the matching 10-Q; Q4 is derived as full-year minus nine-month YTD because XBRL doesn't tag Q4 as its own period. EPS Basic and EPS Diluted are reported directly by the filer. Per-share values are split-adjusted to the current share count (2 split s since 2023).
For the exact XBRL concepts and formulas, see the methodology reference for EPS, FCF per share, the Q4 derivation, and split adjustment.
RGBP CIK 0001589150 Source: EDGAR filings · all facts